p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate

Journal of Surgical Oncology

Volumn 93, Issue 3, 2006, Pages 241-252

  Galizia, Gennaro ^a   Ferraraccio, Francesca ^a   Lieto, Eva ^a   Orditura, Michele ^a   Castellano, Paolo ^a   Imperatore, Vincenzo ^a   La Manna, Giovanni ^a   Pinto, Margherita ^a   Ciardiello, Fortunato ^a   La Mura, Anna ^a   De Vita, Ferdinando ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cyclins; Gastric cancer; Metallothionein; Molecular markers; p27

Indexed keywords

CYCLIN B1; CYCLIN D3; METALLOTHIONEIN; MOLECULAR MARKER; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RECURRENCE RISK; RELAPSE; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYCLIN B; CYCLINS; DOWN-REGULATION; FEMALE; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; METALLOTHIONEIN; MIDDLE AGED; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33644904976     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20402     Document Type: Article

References (43)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Nashimoto A. Nakajima T, Furukawa H, et al.: Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan clinical oncology group 9206-1. J Clin Oncol 2003;12:2282-2287.
3. Chipponi J, Huguier M, Pezet D, et al.: Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg 2004;187:440-445.
4. Hartgrink HH, van de Velde H, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004;22:2069-2077.
5. Dhar DK, Kubota H, Kinukawa N, et al.: Prognostic significance of metastatic lymph node size in patients with gastric cancer. Br J Surg 2003;90:1522-1530.
6. Mullaney PJ, Wadley MS, Hyde C, et al.: Appraisal of compliance with the UICC/AJCC staging system in the staging of gastric cancer. Union Internacional Contra 1a Cancrum/American Joint Committee on Cancer. Br J Surg 2002;89:1405-1408.
7. Falcone A: Future strategies and adjuvant treatment of gastric cancer. Ann Oncol 2003;14:45-47.
8. Lenz HJ: Molecular markers in gastrointestinal cancer: Targeted therapy and tailored chemotherapy. Onkologie 2004;27:12-14.
9. Sutter AP, Zeitz M, Scherübl H: Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 2004;27:17-21.
10. Hiyama T, Tanaka S, Yoshihara M, et al.: Chromosomal and microsatellite instability in sporadic gastric cancer. J Gastroenterol Hepatol 2004;19:756-760.
11. Yao JC, Wang L, Wei D, et al.: Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004;10:4109-4117.
12. Hofler H, Becker KF: Molecular mechanisms of carcinogenesis in gastric cancer. Recent Results Cancer Res 2003;162:65-72.
13. Kitazono AA, Garza DA, Kron SJ: Mutations in the yeast cyclin-dependent kinase Cdc28 reveal a role in the spindle assembly checkpoint. Mol Genet Genomics 2003;269:672-684.
14. 1 phase cyclins in human gastric cancer and gastric mucosa of first-degree relatives. Dig Dis Sci 2002;47:1248-1256.
15. Gammon MD, Terry MB, Arber N, et al.: Nonsteroidal antiinflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: A population-based study. Cancer Epidemiol Biomarkers Prev 2004;13:34-39.
16. Brien TP, Depowski PL, Sheehan CE, et al.: Prognostic factors in gastric cancer. Mod Pathol 1998;11:870-877.
17. Yasuda M, Takesue F, Inutsuka S, et al.: Overexpression of cyclin Bl in gastric cancer and its clinicopathological significance: An immunohistological study. J Cancer Res Clin Oncol 2002;128:412-416.
18. Motwani M, Rizzo C, Sirotnak F, et al.: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;2:549-555.
19. Sherr CJ: Cancer cell cycles. Science 1996;274:1672-1677.
20. kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci 1997;94:6380-6385.
21. Thomas GV, Szigeti K, Murphy M, et al.: Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-687.
22. Kip1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-4081.
23. Halvorsen OJ, Haukaas SA, Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-1479.
24. Galizia G, Lieto E, Ferraraccio F, et al.: Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 2004;10:3490-3499.
25. Feakins RM, Mulcahy HE, Quaglia A, et al.: p27(Kip1) loss does not predict survival in patients with advanced gastric carcinoma. Cancer 2000;89:1684-1691.
26. So JB, Samarasinge K, Raju GC, et al.: Expression of cell-cycle regulators p27 and cyclin E correlates with survival in gastric carcinoma patients. J Surg Res 2000;94:56-60.
27. Kip1 expression and survival in NO gastric carcinoma. Pathol Res Pract 2001;197:231-236.
28. Liu XP, Kawauchi S, Oga A, et al.: Combined examination of p27(Kip1), p21(Waf1/Cip1), and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 2001;39:603-610.
29. Wiksten JP, Lundin J, Nordling S, et al.: The prognostic value of p27 in gastric cancer. Oncology 2002;63:180-184.
30. Nitti D, Belluco C, Mammano E, et al.: Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 2002;81:167-175.
31. Chetty R: p27 protein and cancers of the gastrointestinal tract and liver: An overview. J Clin Gastroenterol 2003;37:23-27.
32. Janssen MA, van Duijn W, Kubben FJ, et al.: Prognostic significance of metallothionein in human gastrointestinal cancer. Clin Cancer Res 2002;8:1889-1896.
33. Tuccari G, Giuffre G, Arena F, et al.: Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol Histopathol 2000;15:1035-1041.
34. Deng D, El-Rifai W, Ji J, et al.: Hypermetilation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 2003;24:25-29.
35. Monden N, Abe S, Sutoh I, et al.: Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-pi, and P-glycoprotein in curatively resected gastric cancer. Oncology 1997;54:391-399.
36. Ebert MP, Gunther T, Hoffman J, et al.: Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res 2000;60:1995-2001.
37. Cherian MG, Jayasurya A, Bay BH: Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003;533:201-209.
38. Theocaris SE, Margeli AP, Koutselinis A: Metallothionein: A functional protein from toxicity to cancer. Int J Biol Markers 2003;18:162-169.
39. Eguchi H, Herschenhous N, Kuzushita N, et al.: Helicobacter pylori increases proteasome-mediated degradation of p27(kip1) in gastric epithelial cells. Cancer Res 2003;15:4739-4746.
40. Grogg KL, Lohse CM, Pankratz VS, et al.: Lymphocyte-rich gastric cancer: Associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003;16:641-651.
41. Kalbfleisch JD, Prentice RL: The statistical analysis of failure time data. New York: Wiley; 1980.
42. Alberts SR, Cervantes A, van de Velde CJ: Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003;14:31-36.
43. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotheapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.